Publication details
Inhibitory kinázy Haspin
| Title in English | Haspin kinase inhibitors |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| Description | Protein kinases are particularly interesting therapeutic targets for modern cancer therapy; to date, more than 35 low molecular weight inhibitors have been approved for clinical use. While some kinases have long been established as attractive targets for pharmacological inhibition, others have come to the fore relatively recently. Haspin kinase inhibitors exhibit attractive broad-spectrum antitumor activity in cell lines. In addition, the existing lead compound MU1464 also has a good pharmacokinetic profile, making it highly likely that these compounds may be therapeutically useful in vivo. |
| Related projects: |